Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Kuilman MM, Ellappalayam A, Barcaru A, Haan JC, Bhaskaran R, Wehkamp D, Menicucci AR, Audeh WM, Mittempergher L, Glas AM. Kuilman MM, et al. Among authors: menicucci ar. Breast Cancer Res Treat. 2022 Oct;195(3):263-274. doi: 10.1007/s10549-022-06698-x. Epub 2022 Aug 19. Breast Cancer Res Treat. 2022. PMID: 35984580 Free PMC article.
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. Rastogi P, et al. Among authors: menicucci ar. J Clin Oncol. 2024 Oct 20;42(30):3561-3569. doi: 10.1200/JCO.23.01995. Epub 2024 Jul 24. J Clin Oncol. 2024. PMID: 39047219 Free PMC article. Clinical Trial.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth PW, et al. Among authors: menicucci ar. JCO Precis Oncol. 2022 Apr;6(1):e2100463. doi: 10.1200/PO.21.00463. JCO Precis Oncol. 2022. PMID: 35476550 Free PMC article.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Whitworth PW, et al. Among authors: menicucci ar. JCO Precis Oncol. 2022 Sep;6:e2200197. doi: 10.1200/PO.22.00197. JCO Precis Oncol. 2022. PMID: 36108259 Free PMC article.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Nash CH 3rd, Murray MK, Richards PD, Gittleman M, Budway R, Rahman RL, Kelemen P, Dooley WC, Rock DT, Cowan K, Lesnikoski BA, Barone JL, Ashikari AY, Dupree B, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth P, et al. Among authors: menicucci ar. Ann Surg Oncol. 2022 Apr 4;29(7):4141-52. doi: 10.1245/s10434-022-11666-2. Online ahead of print. Ann Surg Oncol. 2022. PMID: 35378634 Free PMC article.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J. Yuan Y, et al. Oncologist. 2021 Mar;26(3):e382-e393. doi: 10.1002/onco.13574. Epub 2020 Nov 8. Oncologist. 2021. PMID: 33098195 Free PMC article. Clinical Trial.
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.
van 't Veer LJ, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Van de Velde CJH, Kleijn M, Dreezen C, Menicucci AR, Audeh W, Liefers GJ. van 't Veer LJ, et al. Among authors: menicucci ar. JAMA Netw Open. 2024 Nov 4;7(11):e2447530. doi: 10.1001/jamanetworkopen.2024.47530. JAMA Netw Open. 2024. PMID: 39602119 Free article. Clinical Trial.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz LE, Yoder EB, van der Baan B, Menicucci AR, Dauer P, Audeh W, Cox CE. Blumencranz P, et al. Among authors: menicucci ar. Ann Surg Oncol. 2023 Dec;30(13):8353-8361. doi: 10.1245/s10434-023-14027-9. Epub 2023 Sep 1. Ann Surg Oncol. 2023. PMID: 37658272 Free PMC article.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV, Beitsch PD, Rock DT, Budway RJ, Dul CL, Kelemen PR, Ashikari AY, Baron PL, Weinstein PD, Mislowsky A, Lee LA, Beatty J, Murray MK, Dupree BB, Finn C, Corcoran K, Wang S, Menicucci AR, Yoder EB, Blumencranz LE, Dauer P, Audeh W, Whitworth PW; NBRST Investigators Group. Pellicane JV, et al. Among authors: menicucci ar. Surg Oncol. 2022 Dec;45:101885. doi: 10.1016/j.suronc.2022.101885. Epub 2022 Nov 22. Surg Oncol. 2022. PMID: 36436423 Free article.
21 results